Comparative Evaluation of Complications in Untreated and Recurrent Urinary Tract Infections
Renal Dysfunction, Urosepsis, Antibiotic Resistance, and Quality of Life
DOI:
https://doi.org/10.69750/dmls.01.010.068Keywords:
Urinary tract infections, biomarkers, renal function, inflammation, oxidative stress, antibiotic resistanceAbstract
Background: Urinary tract infections (UTIs) are common but can cause severe complications if untreated or recurrent, affecting renal function and antibiotic resistance. This study uniquely uses biomarkers such as CRP, NGAL, IL-6, and TNF-α to predict renal dysfunction and antibiotic resistance, highlighting their clinical significance.
Objectives: To compare the complications of untreated and recurrent UTIs concerning renal function, systemic inflammation, oxidative stress, and antibiotic resistance using biomarker analysis.
Methods: A comparative study was conducted on 500 adult patients (2022–2024) from two tertiary care hospitals. Patients were categorized into recurrent UTIs (≥3 episodes/year) and untreated UTIs (≥1 month without antibiotics). Biomarkers for renal dysfunction (creatinine, eGFR, NGAL), inflammation (CRP, IL-6, TNF-α, procalcitonin), and oxidative stress (MDA, KIM-1) were analyzed. Multivariate regression and statistical tests assessed predictors and significance.
Results: Untreated UTIs were associated with significantly worse renal outcomes (creatinine: 2.1±0.4 mg/dL, eGFR: 54.2±6.1; p<0.001), higher inflammation (CRP: 35.7±5.9 mg/L; procalcitonin: 2.1±0.6 ng/mL; p<0.001), and elevated oxidative stress (MDA: 6.7±1.3 μmol/L). Recurrent UTIs had higher multidrug resistance rates (45% vs 28%, p=0.002). CRP, NGAL, and procalcitonin independently predicted renal dysfunction, while IL-6 and TNF-α were strong predictors of antibiotic resistance.
Conclusions: Untreated UTIs pose severe risks for renal health and systemic inflammation, while recurrent UTIs increase antibiotic resistance. Biomarkers offer valuable predictive tools for early intervention, improving patient outcomes.
Downloads
References
Mancuso G, Midiri A, Gerace E, Marra M, Zummo S, Biondo C. Urinary Tract Infections: The Current Scenario and Future Prospects. Pathogens [Internet]. 2023; 12(4).doi: 10.3390/pathogens12040623
Antinori S, Pezzani MD. Uncomplicated and Complicated Urinary Tract Infections in Adults: The Infectious Diseases’s Specialist Perspective. In: Tonolini M, editor. Imaging and Intervention in Urinary Tract Infections and Urosepsis. Cham: Springer International Publishing; 2018. p. 17-33.doi: 10.1007/978-3-319-68276-1_3
Meena P, Bhargava V, Rana DS, Bhalla AK. Urinary Tract Infection in Renal Transplant Recipient: A Clinical Comprehensive Review. Saudi Journal of Kidney Diseases and Transplantation. 2021;32(2):307-17.doi: 10.4103/1319-2442.335441
Petrosillo N, Granata G, Boyle B, Doyle MM, Pinchera B, Taglietti F. Preventing sepsis development in complicated urinary tract infections. Expert Review of Anti-infective Therapy. 2020;18(1):47-61.doi: 10.1080/14787210.2020.1700794
Wagenlehner FME, Bjerklund Johansen TE, Cai T, Koves B, Kranz J, Pilatz A, et al. Epidemiology, definition and treatment of complicated urinary tract infections. Nature Reviews Urology. 2020;17(10):586-600.doi: 10.1038/s41585-020-0362-4
Haddad JM, Ubertazzi E, Cabrera OS, Medina M, Garcia J, Rodriguez-Colorado S, et al. Latin American consensus on uncomplicated recurrent urinary tract infection—2018. International Urogynecology Journal. 2020;31(1):35-44.doi: 10.1007/s00192-019-04079-5
Marantidis J, Sussman RD. Unmet Needs in Complicated Urinary Tract Infections: Challenges, Recommendations, and Emerging Treatment Pathways. Infection and Drug Resistance. 2023;16(null):1391-405.doi: 10.2147/IDR.S382617
Bader MS, Loeb M, Brooks AA. An update on the management of urinary tract infections in the era of antimicrobial resistance. Postgraduate Medicine. 2017;129(2):242-58.doi: 10.1080/00325481.2017.1246055
Osamwonyi B, Foley C. Management of recurrent urinary tract infections in adults. Surgery (Oxford). 2017;35(6):299-305.doi: https://doi.org/10.1016/j.mpsur.2017.03.004
Hollyer I, Ison MG. The challenge of urinary tract infections in renal transplant recipients. Transplant Infectious Disease. 2018;20(2):e12828.doi: https://doi.org/10.1111/tid.12828
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature Reviews Microbiology. 2015;13(5):269-84.doi: 10.1038/nrmicro3432
Beetz R, Westenfelder M. Antimicrobial therapy of urinary tract infections in children. International Journal of Antimicrobial Agents. 2011;38:42-50.doi: https://doi.org/10.1016/j.ijantimicag.2011.09.006
Kamei J, Yamamoto S. Complicated urinary tract infections with diabetes mellitus. Journal of Infection and Chemotherapy. 2021;27(8):1131-6.doi: https://doi.org/10.1016/j.jiac.2021.05.012
Moussa M, Abou Chakra M, Dellis A, Moussa Y, Papatsoris A. Pharmacotherapeutic advances for recurrent urinary tract infections in women. Expert Opinion on Pharmacotherapy. 2020;21(16):2011-26.doi: 10.1080/14656566.2020.1795128
Roy RR, Tonny RT, Sultana N, Mamun AA, Jesmin T. A Contemporary Overview of Urinary Tract Infection (UTI) in Children. Paediatric Nephrology Journal of Bangladesh. 2022;7(1):19-28.doi: 10.4103/pnjb.pnjb_10_22
Batirel A, Regmi SK, Singh P, Mert A, Konety BR, Kumar R. Urological infections in the developing world: an increasing problem in developed countries. World Journal of Urology. 2020;38(11):2681-91.doi: 10.1007/s00345-020-03120-3
Cornelius SA, Basu U, Zimmern PE, De Nisco NJ. Overcoming challenges in the management of recurrent urinary tract infections. Expert Review of Anti-infective Therapy.1-13.doi: 10.1080/14787210.2024.2412628
Bharuka V, Meshram R, Munjewar PK. Comprehensive Review of Urinary Tract Infections in Renal Transplant Recipients: Clinical Insights and Management Strategies. Cureus. 2024;16(2):e53882.doi: 10.7759/cureus.53882
Downloads
PlumX Metrics
Published
Issue
Section
License
Copyright (c) 2024 DEVELOPMENTAL MEDICO-LIFE-SCIENCES
This work is licensed under a Creative Commons Attribution 4.0 International License.
The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/public domain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
